Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 6, 2025SDÜ Tıp Fakültesi DergisiOpen Access

Evaluation of Ceftazidime-Avibactam Susceptibility in Carbapenem-Resistant Gram-Negative Bacteria

View Full Paper
Ask AI
Bookmark
Share

Authors

YŞYaren ŞekercioğluEÇEmel Sesli Çetin

Discussion

Loading...

Member takes

Overview

Evaluation reveals ceftazidime-avibactam susceptibility in gram-negative bacteria, suggesting effective treatment strategies for resistance.

Key Points

  • Ceftazidime-avibactam susceptibility reached 90.9% in Pseudomonas aeruginosa, underscoring treatment options.
  • Susceptibility rates showed variability with 87.8% for Klebsiella pneumoniae via DDM and 74.1% by automated testing.
  • Evaluation through Kirby-Bauer disk diffusion method and BD Phoenix automated system demonstrated critical discrepancies.
  • Further species-specific studies are needed to enhance accuracy in interpreting ceftazidime-avibactam testing results.

Cite This Study

Şekercioğlu et al. (2025) studied this question.

synapsesocial.com/papers/69337cfbb3f947a0a125a774https://doi.org/10.17343/sdutfd.1748282
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Molecular Epidemiology of Infections Caused by Carbapenem-Resistant <em>Pseudomonas aeruginosa</em> and Enterobacterales and Susceptibility of Isolates to Ceftazidime-Avibactam2025
  2. 2Molecular Epidemiology of Carbapenem-Resistant P. aeruginosa and Enterobacterales Isolates from Clinical Infections and Their Susceptibility to Ceftazidime–Avibactam2025
  3. 3Emergence and dissemination of <i>bla</i> <sub>KPC-31</sub> and <i>bla</i> <sub>PAC-2</sub> among different species of Enterobacterales in Colombia: a new challenge for the microbiological laboratories2025
  4. 4Comparison of Antimicrobial Activity between Ceftriaxone-Sulbactam-Disodium EDTA and Ceftazidime-Avibactam against Carbapenemase Producing Enterobacterales Isolates from a Tertiary Care Hospital: An In-vitro Study2025
  5. 5Continuous infusion versus intermittent dosing of ceftazidime/avibactam in critically ill patients with Klebsiella pneumoniae OXA-48 or Pseudomonas aeruginosa infections: a single-center randomized open-label trial (ZAVICONT). Rationale and design2025